Nucleoside-triphosphatase, cancer-related (NTPCR)

Nucleoside-triphosphatase, cancer-related (NTPCR) is a human enzyme characterized as a non-specific nucleoside triphosphatase. It hydrolyzes multiple nucleoside triphosphates (including ATP, GTP, CTP, TTP, and UTP) in vitro, with slower activity than classical NTPases[1][2][3]. NTPCR is overexpressed in a variety of tumor tissues and has been specifically studied in epithelial ovarian carcinoma, where high NTPCR expression correlates with tumor-suppressive properties such as reduced cell proliferation, migration, and invasion[2]. The protein contains conserved Walker A and Walker B motifs characteristic of the AAA+ ATPase superfamily[1]. Although NTPCR is not essential for cell survival, its overexpression can be cytotoxic, independent of its enzymatic activity[3]. Functional and omics analyses suggest that NTPCR modulates pathways including cell cycle progression, apoptosis, and metabolism, but drug interactions and therapeutic targeting remain unexplored. Its putative role as a tumor suppressor and potential prognostic biomarker in certain cancers is under active research[2][3][4].

Other names

Cancer-related nucleoside-triphosphataseNTPaseHCR-NTPaseC1orf57MGC13186THEP1Nucleoside triphosphate phosphohydrolasehuman cancer-related NTPase